A incidência de distúrbios de movimento específicos associados a antipsicóticos foi de 23,9% no grupo INVEGA ([R]) SUSTENNA ([R]) e 18,8% no grupo de antipsicóticos orais. Um aumento> = 7% no peso afetou 32,4% dos indivíduos no grupo INVEGA ([R]) SUSTENNA ([R]) e 14,4% no grupo de antipsicóticos orais. Os EAs do estudo devem ser avaliados dentro do contexto do desenho do estudo e da população do estudo.
Incidence of specific movement disorders associated with antipsychotics was 23.9% in the INVEGA([R]) SUSTENNA([R]) group and 18.8% in the oral antipsychotic group. A >=7% increase in weight affected 32.4% of subjects in the INVEGA([R]) SUSTENNA([R]) group and 14.4% in the oral antipsychotic group. The study AEs should be evaluated within the context of the trial design and study population.
Landmark Study Shows Once-Monthly Long-Acting Therapy INVEGA[R] SUSTENNA[R] paliperidone palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia Compared to Daily Oral Antipsychotics. (2014, May 19). Clinical Trials Week, 432. https://link.gale.com/apps/doc/A370045678/AONE?u=capes&sid=bookmark-AONE&xid=11b48d25
Nenhum comentário:
Postar um comentário